Featured News

On August 24, Rep. Betty McCollum launched the bipartisan Celiac Disease Caucus. We look forward to continuing to work with Rep. McCollum and the Caucus to support innovative research and advance legislation that will ease the suffering of celiac patients.

Please take one minute to email your Members of Congress to make it easier and safer for those with celiac disease to purchase food items by requiring labels to list the presence of barley and rye, in addition to wheat.

The FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

A recent study published in JAMA Network, using two decades worth of dietary data, concluded that gluten consumption in people without celiac disease did not impair cognitive function.

Each year, we look forward to May Celiac Awareness Month for the chance to celebrate our community’s tireless work.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

We are determined to use every resource at our disposal, including strategic funding of research and advocacy, to help discover and bring to the celiac disease patient community therapeutic alternatives to the gluten-free diet.